What is SANA's market cap?

$766.36M, based on the Nov 4 close of $2.56.

Does Sana Biotechnology pay a dividend?

No regular cash dividend has been paid in the last year.

How much of SANA is sold short?

40.8M shares, 22.2% of float, as of Oct 15, 2026.

What sector is SANA in?

Healthcare, in the Biotechnology industry.

NASDAQ · SANAHealthcareBiotechnology

Sana Biotechnology, Inc. Common Stock (SANA)

$2.56+4.92%

Close Nov 4, 2026 · split-adjusted

Nov 2, 2026$2.40▼ 47.48% in range

Nov 3, 2025Low $2.27 · High $5.18Nov 2, 2026

What changed · written from our data

As of Nov 4, 2026

Sana Biotechnology closed at $2.56 on Nov 4, up 4.92%, 50.6% below its 52-week closing high. Volume of 2.6M shares was 0.91× its 20-day average (close to normal).

Split-adjusted performance: -6.9% over one month, -29.7% over six months, -44.0% over one year.

Short interest was 40.8M shares at the Oct 15 settlement, up 5.5% from the prior report (22.2% of float, 11.0 days to cover).

Market cap$766.4M299.4M shares

Revenue · quarter$0.00—

Diluted EPS$-0.22—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range2.27 – 5.18−50.6% from high

Volume2.6M0.91× 20-day avg

Volatility · 60d72.6%Annualised

Short % of float22.2%11.0 days to cover

Net cash$160.5MCash $160.5M

Next earnings—Not scheduled

Split-adjusted performance

1W −2.7%1M −6.9%3M −24.9%6M −29.7%YTD −37.1%1Y −44.0%3Y −13.5%5Y −87.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum43

Revenue growth—

Net margin—

Value (low P/E)—

Size68

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short40.8M+5.5% vs prior

Days to cover11.0Settled Oct 15

% of float22.2%

Short vol. 10d57.1%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
SANASana Biotechnology	$2.56	+4.92%	−29.7%	—	—	—	$766.4M
DNAGinkgo Bioworks Holdings	$11.65	+8.27%	+15.6%	−48.5%	−231.7%	—	$784.5M	Compare
CGEMCullinan Therapeutics	$12.49	−20.70%	−16.7%	—	—	—	$803.8M	Compare
ATTOAttovia Therapeutics	$15.60	+2.16%	—	—	—	—	$712.2M	Compare
SLDBSolid Biosciences	$6.52	+3.82%	−9.4%	—	—	—	$699.1M	Compare
CADLCandel Therapeutics	$9.05	+2.61%	+18.6%	—	—	—	$692.5M	Compare
AURAAura Biosciences	$6.65	+6.57%	−19.8%	—	—	—	$689.6M	Compare
FDMT4D Molecular Therapeutics	$12.28	+2.76%	+17.9%	+25106.7%	−1929.0%	—	$678.4M	Compare
PRMEPrime Medicine	$4.97	+9.23%	+45.7%	+3.5%	−3649.0%	—	$901.4M	Compare

News about Sana Biotechnology

All news →

Stock Market Today: Dow Jones, S&P 500 Futures Rise As JD Vance Touts 'Good Deal' If Iran Meets US 'Red Lines'—Sana, Chevron In FocusBenzinga · Apr 14, 2026▲ Positive

Quick answers

What does Sana Biotechnology do?: Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases.
What is SANA's market cap?: $766.36M, based on the Nov 4 close of $2.56.
Does Sana Biotechnology pay a dividend?: No regular cash dividend has been paid in the last year.
How much of SANA is sold short?: 40.8M shares, 22.2% of float, as of Oct 15, 2026.
What sector is SANA in?: Healthcare, in the Biotechnology industry.

About Sana Biotechnology

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.

HQ: Seattle, WA142 employeesListed Feb 4, 2021sana.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology